Clinical Trial Update: Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating G-202 in PSMA-positive glioblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• G-202

Snippet

Sponsor: GenSpera, Inc. | Conditions: Glioblastoma | Phase 2 | Status: WITHDRAWN